As society enters a super-aged demographic, medical research increasingly treats aging as a controllable biological process that drives multiple chronic conditions and functional declines. Advanced regenerative medicine, which traditionally focuses on cell and gene therapies to repair damaged tissues, is expanding its scope to target age-related physical deterioration. However, establishing aging as a formal medical indication requires new clinical trial designs, validated biomarkers, and distinct regulatory pathways.
Forum Sessions Examine Aging Biology and Regulatory Pathways
The program features three distinct sessions designed to bridge laboratory discoveries with clinical applications. The first session, titled “Why Aging Now,” investigates the shifting medical paradigm that views aging as a treatable biological target and evaluates the role of longevity research in an era centered on healthspan. The second session covers the fundamentals of biological aging measurement, target discovery, and recent clinical development pipelines.
The final segment features a panel discussion dedicated to the regulatory hurdles and clinical trial requirements facing anti-aging indications. Experts will debate the evidentiary thresholds necessary for regulatory approval and institutional support.
Registration and Event Logistics for Attendees
Advance registration for the forum remains open through October 23.
Frequently Asked Questions About the 2026 Regenerative Medicine Forum
Where and when is the 2026 Advanced Regenerative Medicine Future Strategy Forum taking place?
The event is scheduled for October 28 at the Westin Josun Seoul.
What is the deadline for event registration?
Attendees must complete their advance registration by October 23.
What core topics will the panel discussion cover?
The panel discussion focuses on the clinical challenges of establishing aging as a medical indication. Participants will evaluate the scientific evidence and regulatory frameworks required to bring anti-aging therapies through clinical trials.